Last Updated: September 24, 2026

Details for Patent: 11,534,444

Name: Drug Patent Intelligence for US Patent 11534444
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,534,444 protect, and when does it expire?

Patent 11,534,444 protects EVRYSDI and is included in two NDAs.

This patent has twenty-two patent family members in eleven countries.

Summary for Patent: 11,534,444

Title:	Treatment of SMA
Abstract:	The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
Inventor(s):	Jean-Paul Pfefen, Heidemarie Kletzl, Lutz Mueller
Assignee:	Hoffmann La Roche Inc
Application Number:	US16/838,942
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,534,444
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 11,534,444

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	EVRYSDI	risdiplam	FOR SOLUTION;ORAL	213535-001	Aug 7, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF SPINAL MUSCULAR ATROPHY	⤷ Start Trial
Genentech Inc	EVRYSDI	risdiplam	TABLET;ORAL	219285-001	Feb 11, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF SPINAL MUSCULAR ATROPHY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,534,444

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018344402	⤷ Start Trial
Australia	2024266812	⤷ Start Trial
Canada	3078137	⤷ Start Trial
China	111182900	⤷ Start Trial
China	117919251	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.